Review of evolving pharmacological and biomarker strategies for stratifying and treating progressive metabolic steatohepatitis towards personalized care.
Key Takeaways
- G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
- Numerous late-stage clinical trials have advanced the therapeutic landscape of MASH
- This suggests that optimal treatment efficacy will require stratified and potentially combinatorial approaches